At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02105 LAEKNA-B
Not Yet Opened 12-19 16:08:47
9.100
-0.470
-4.91%
High10.880Low8.930Vol19.38M
Open9.110D1 Closing9.570Amplitude20.38%
Mkt Cap3.71BTradable Cap3.71BTotal Shares408.00M
T/O190.06MT/O Rate4.75%Tradable Shares408.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Stock Track | Laekna Plummets 5.08% as Phase I Trial Update Fails to Impress Investors
Stock Track  ·  12-04
Stock Track | Laekna Plummets 5.08% as Phase I Trial Update Fails to Impress Investors
Laekna Doses All Subjects in LAE102 Phase I Trial
MT Newswires Live  ·  12-04
Laekna Doses All Subjects in LAE102 Phase I Trial
Laekna Obesity Drug Begins Clinical Study
MT Newswires Live  ·  11-28
Laekna Obesity Drug Begins Clinical Study
Stock Track | LAEKNA-B Soars 5.77% as Muscle Weakness Drug Study Commences
Stock Track  ·  11-28
Stock Track | LAEKNA-B Soars 5.77% as Muscle Weakness Drug Study Commences
Laekna Starts Investigational New Drug-Enabling Study for Muscle Weakness Pill
MT Newswires Live  ·  11-28
Laekna Starts Investigational New Drug-Enabling Study for Muscle Weakness Pill
BUZZ-China's Laekna falls most in 7 months on discounted share sale
Reuters  ·  11-21
BUZZ-China's Laekna falls most in 7 months on discounted share sale
Laekna Seeks HK$230 Million in Placement Deal; Shares Fall 9%
MT Newswires Live  ·  11-21
Laekna Seeks HK$230 Million in Placement Deal; Shares Fall 9%
Stock Track | Laekna's Shares Plummet 10.94% on Plan to Place 17.6 Million New Shares
Stock Track  ·  11-21
Stock Track | Laekna's Shares Plummet 10.94% on Plan to Place 17.6 Million New Shares
BRIEF-Laekna To Place Aggregate 17.6 MLN Shares At Hk$13.36 Per Share
Reuters  ·  11-21
BRIEF-Laekna To Place Aggregate 17.6 MLN Shares At Hk$13.36 Per Share
Laekna Inc - Placing of New Shares
THOMSON REUTERS  ·  11-21
Laekna Inc - Placing of New Shares
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Reuters  ·  11-20
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Laekna Inc - Lilly to Fund and Share Resources for Lae102 Development
THOMSON REUTERS  ·  11-20
Laekna Inc - Lilly to Fund and Share Resources for Lae102 Development
Laekna Announces a Clinical Collaboration With Lilly to Develop Lae102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2a for the Treatment of Obesity
THOMSON REUTERS  ·  11-20
Laekna Announces a Clinical Collaboration With Lilly to Develop Lae102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2a for the Treatment of Obesity
Laekna Inc - Retains Global Rights for Lae102
THOMSON REUTERS  ·  11-20
Laekna Inc - Retains Global Rights for Lae102
US-Based Eli Lilly to Fund US Phase 1 Study for Laekna's Weight Loss Drug
MT Newswires Live  ·  11-20
US-Based Eli Lilly to Fund US Phase 1 Study for Laekna's Weight Loss Drug
Stock Track | LAEKNA-B Soars 43% on Obesity Drug Deal With Eli Lilly
Stock Track  ·  11-20
Stock Track | LAEKNA-B Soars 43% on Obesity Drug Deal With Eli Lilly
BRIEF-Laekna Inc Announces Clinical Collaboration With Lilly
Reuters  ·  11-20
BRIEF-Laekna Inc Announces Clinical Collaboration With Lilly
BUZZ-HK-listed Laekna hits 10-month peak on Eli Lilly deal
Reuters  ·  11-20
BUZZ-HK-listed Laekna hits 10-month peak on Eli Lilly deal
Laekna Inc - Clinical Collaboration With Lilly on Lae102 in U.S. for Treatment of Obesity
THOMSON REUTERS  ·  11-20
Laekna Inc - Clinical Collaboration With Lilly on Lae102 in U.S. for Treatment of Obesity
Stock Track | Laekna Soars as Obesity Drug Shows Promise in Clinical Trials
Stock Track  ·  10-20
Stock Track | Laekna Soars as Obesity Drug Shows Promise in Clinical Trials

Introduction

Company Name.
LAEKNA-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer, liver diseases and obesity. The Company is still in the research and development stage. The Company's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The Company mainly conducts business in the Chinese, America, European, Korean, and other markets.
Issue price:
--